The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Please provide your email address to receive an email when new articles are posted on . All men with BRCA2 mutations treated with olaparib monotherapy achieved at least a 50% decline in PSA. The study ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer. AUSTIN, ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...